Statement: The majority of patients in the primary trial had an EGFR Expression level of 0, and 0 patients had an EGFR of 3 or above.
Primary_evidence: Outcome Measurement:    Level of EGFR Expression   Estimated at the end of the trial Immunoreactivity will be evaluated qualitatively with regard to intensity as follows: Measured on a scale, ranging from 0-3+ 0=negative (no immunoreactivity) 1+ - 3+ = positive:   faint immunoreactivity (weak staining)   intense immunoreactivity (strong staining) Immunohistochemical studies will be performed on the tumor specimen to correlate the anti-tumor efficacy of OSI-774 and bevacizumab with pre-treatment molecular characteristics.   Time frame: Up to 12 years Results 1:    Arm/Group Title: Treatment (Erlotinib Hydrochloride, Bevacizumab)   Arm/Group Description: Patients receive erlotinib hydrochloride PO QD on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.   Overall Number of Participants Analyzed: 38   Measure Type: Number   Unit of Measure: participants  EGFR 0: 24 EGFR 1+: 8 EGFR 2+: 4   EGFR 3+: 0   Insufficient tumor tissue: 2